Selected research
Industry Research
Peptide-Radionuclide Conjugates (PRCs) Industry Research Report 2026
Market perspective
The global Peptide-Radionuclide Conjugates (PRCs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Peptide-Radionuclide Conjugates (PRCs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Peptide-Radionuclide Conjugates (PRCs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Peptide-Radionuclide Conjugates (PRCs) include Grand Pharmaceutical, Novartis, Telix Pharmaceutical, RadioMedix, ITM Radiopharma and Curium Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Peptide-Radionuclide Conjugates (PRCs) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide-Radionuclide Conjugates (PRCs) Market by Company
Grand Pharmaceutical
Novartis
Telix Pharmaceutical
RadioMedix
ITM Radiopharma
Curium Pharma
Peptide-Radionuclide Conjugates (PRCs) Segment by Type
Diagnostic PRCs
Therapeutic PRCs
Peptide-Radionuclide Conjugates (PRCs) Segment by Application
Prostate Cancer
Neuroendocrine Tumors
Other
Peptide-Radionuclide Conjugates (PRCs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Radionuclide Conjugates (PRCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide-Radionuclide Conjugates (PRCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Radionuclide Conjugates (PRCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Peptide-Radionuclide Conjugates (PRCs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Peptide-Radionuclide Conjugates (PRCs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Peptide-Radionuclide Conjugates (PRCs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Diagnostic PRCs
- Therapeutic PRCs
Applications
- Prostate Cancer
- Neuroendocrine Tumors
- Other
Companies covered
- Grand Pharmaceutical
- Novartis
- Telix Pharmaceutical
- RadioMedix
- ITM Radiopharma
- Curium Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size (2021-2032)
- 2.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales (2021-2032)
- 2.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Market Average Price (2021-2032)
- 2.3 Peptide-Radionuclide Conjugates (PRCs) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Diagnostic PRCs
- 2.3.3 Therapeutic PRCs
- 2.4 Peptide-Radionuclide Conjugates (PRCs) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Prostate Cancer
- 2.4.3 Neuroendocrine Tumors
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue of Manufacturers (2021-2026)
- 3.4 Global Peptide-Radionuclide Conjugates (PRCs) Average Price by Manufacturers (2021-2026)
- 3.5 Global Peptide-Radionuclide Conjugates (PRCs) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Product Type & Application
- 3.8 Global Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Established Date
- 3.9 Global Peptide-Radionuclide Conjugates (PRCs) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Grand Pharmaceutical
- 4.1.1 Grand Pharmaceutical Company Information
- 4.1.2 Grand Pharmaceutical Business Overview
- 4.1.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
- 4.1.5 Grand Pharmaceutical Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Telix Pharmaceutical
- 4.3.1 Telix Pharmaceutical Company Information
- 4.3.2 Telix Pharmaceutical Business Overview
- 4.3.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
- 4.3.5 Telix Pharmaceutical Recent Developments
- 4.4 RadioMedix
- 4.4.1 RadioMedix Company Information
- 4.4.2 RadioMedix Business Overview
- 4.4.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
- 4.4.5 RadioMedix Recent Developments
- 4.5 ITM Radiopharma
- 4.5.1 ITM Radiopharma Company Information
- 4.5.2 ITM Radiopharma Business Overview
- 4.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
- 4.5.5 ITM Radiopharma Recent Developments
- 4.6 Curium Pharma
- 4.6.1 Curium Pharma Company Information
- 4.6.2 Curium Pharma Business Overview
- 4.6.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
- 4.6.5 Curium Pharma Recent Developments
5 Global Peptide-Radionuclide Conjugates (PRCs) Market Scenario by Region
- 5.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021-2032
- 5.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021-2026
- 5.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2027-2032
- 5.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2021-2032
- 5.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2021-2026
- 5.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2027-2032
- 5.4 North America Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
- 5.4.1 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
- 5.4.3 North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
- 5.5.1 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
- 5.5.3 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
- 5.7.1 South America Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
- 5.7.3 South America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032)
- 6.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2032)
- 6.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032)
- 6.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2032)
- 6.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032)
- 7.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2032)
- 7.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032)
- 7.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2032)
- 7.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Peptide-Radionuclide Conjugates (PRCs) Value Chain Analysis
- 8.1.1 Peptide-Radionuclide Conjugates (PRCs) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Peptide-Radionuclide Conjugates (PRCs) Production Mode & Process
- 8.2 Peptide-Radionuclide Conjugates (PRCs) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
- 8.2.3 Peptide-Radionuclide Conjugates (PRCs) Customers
9 Global Peptide-Radionuclide Conjugates (PRCs) Analyzing Market Dynamics
- 9.1 Peptide-Radionuclide Conjugates (PRCs) Industry Trends
- 9.2 Peptide-Radionuclide Conjugates (PRCs) Industry Drivers
- 9.3 Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges
- 9.4 Peptide-Radionuclide Conjugates (PRCs) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst